FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019

This retrospective review assesses the frequency of surrogate measures used for the first time vs subsequent times in a cancer setting and the surrogate’s strength of correlation with patient-centered outcomes.

Detalles Bibliográficos
Autores principales: Chen, Emerson Y., Haslam, Alyson, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186918/
https://www.ncbi.nlm.nih.gov/pubmed/32338703
http://dx.doi.org/10.1001/jamainternmed.2020.1097
Descripción
Sumario:This retrospective review assesses the frequency of surrogate measures used for the first time vs subsequent times in a cancer setting and the surrogate’s strength of correlation with patient-centered outcomes.

Ejemplares similares